ImmunityBio, Inc.
corporate_fare Company Profile
ImmunityBio, Inc. (NASDAQ:IBRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for IBRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for IBRX spans 10-Q, 8-K, SCHEDULE 13D/A, DEF 14A.
Recent high-impact activity:
- ImmunityBio 10-Q: Q3 Revenue $48.7M, $334.3M Cash, Going-Concern Warning
- ImmunityBio Q3 Revenue Up 53% to $48.7M; $1.0B Nine-Month Loss Is Mostly Non-Cash
- ImmunityBio Q3 ANKTIVA Sales Jump 53% to $48.7M; Nine-Month Revenue Up 92%
- ANKTIVA Plus BCG Hits Primary Endpoint in BCG-Naïve Bladder Cancer Trial
- ANKTIVA Long-Term Data: 84% Avoid Cystectomy at Three Years, Responses Past 53 Months
Financial Snapshot
Short Interest & Short Volume
10.77 days to coverFINRA reported short interest of 126,083,790 shares in IBRX as of the October 30, 2026 settlement, a 2.6% increase from the prior period — about 10.8 days to cover at its recent average daily volume. On November 20, 2026, 58.3% of IBRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.